Endocrinology of Pregnancy and Parturition

Published on 10/03/2015 by admin

Filed under Obstetrics & Gynecology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3143 times

Chapter 5 Endocrinology of Pregnancy and Parturition

Women undergo major endocrinologic and metabolic changes that establish, maintain, and terminate pregnancy. The aim of these changes is the safe delivery of an infant who can survive outside of the uterus. The maturation of the fetus and the adaptation of the mother are regulated by a variety of hormones. This chapter deals with the properties, functions, and interactions of the most important of these hormones as they relate to pregnancy and parturition.

image Fetoplacental Unit

The concept of the fetoplacental unit is based on observations of the interactions of hormones of fetal and maternal origin. The fetoplacental unit largely controls the endocrine events of the pregnancy. Although the fetus, the placenta, and the mother all provide input, the fetus appears to play the most active and controlling role of the three in its growth and maturation, and probably also in the events that lead to parturition.

image Hormones

The fetoplacental unit produces a variety of hormones to support the maturation of the fetus and the adaptation of the mother.

PEPTIDE HORMONES

Human Chorionic Gonadotropin

Human chorionic gonadotropin (hCG) is secreted by trophoblastic cells of the placenta and maintains pregnancy. This hormone is a glycoprotein with a molecular weight of 40,000 to 45,000 and consists of two subunits: alpha (α) and beta (β). The α subunit is shared with luteinizing hormone (LH) and thyroid-stimulating hormone (TSH). The specificity of hCG is related to its β subunit (β-hCG), and a radioimmunoassay that is specific for the β subunit allows positive identification of hCG. The presence of hCG at times other than pregnancy signals the presence of an hCG-producing tumor, usually a hydatidiform mole, choriocarcinoma, or embryonal carcinoma (a germ cell tumor).

During pregnancy, hCG begins to rise 8 days after ovulation (9 days after the midcycle LH peak). This provides the basis for virtually all immunologic or chemical pregnancy tests. With continuing pregnancy, hCG values peak at 60 to 90 days and then decline to a moderate, more constant level. For the first 6 to 8 weeks of pregnancy, hCG maintains the corpus luteum and thereby ensures continued progesterone output until progesterone production shifts to the placenta. Titers of hCG are usually abnormally low in patients with an ectopic pregnancy or threatened abortion and abnormally high in those with trophoblastic disease (e.g., moles or choriocarcinoma). This hormone may also regulate steroid biosynthesis in the placenta and the fetal adrenal gland and stimulate testosterone production in the fetal testicle. Although immune suppression has been ascribed to hCG, this effect has not been verified.

STEROID HORMONES

Progesterone

Progesterone is the most important human progestogen. In the luteal phase, it induces secretory changes in the endometrium, and in pregnancy, higher levels induce decidual changes. Up to the 6th or 7th week of pregnancy, the major source of progesterone (in the form of 17-OH progesterone) is the ovary. Thereafter, the placenta begins to play the major role. If the corpus luteum of pregnancy is removed before 7 weeks and continuation of the pregnancy is desired, progesterone should be given to prevent spontaneous abortion. Circulating progesterone is mostly bound to carrier proteins, and less than 10% is free and physiologically active.

The myometrium receives progesterone directly from the venous blood draining the placenta. Progesterone prevents uterine contractions and may also be involved in establishing an immune tolerance for the products of conception. Progesterone also suppresses gap junction formation, placental CRH expression, and the actions of estrogen, cytokines, and prostaglandin. This steroid hormone therefore plays a central role in maintaining uterine quiescence throughout most of pregnancy.

The fetus inactivates progesterone by transformation to corticosteroids or by hydroxylation or conjugation to inert excretory products. However, the placenta can convert these inert materials back to progesterone. Steroid biochemical pathways are shown in Figure 5-1.

Glucocorticoids

Cortisol is derived from circulating cholesterol (see Figure 5-1). Maternal plasma cortisol concentrations rise throughout pregnancy, and the diurnal rhythm of cortisol secretion persists. The plasma level of transcortin rises in pregnancy, probably stimulated by estrogen, and the plasma-free cortisol concentration doubles.

Both the fetal adrenal and the placenta participate in cortisol metabolism. The fetal adrenal is stimulated by ACTH, originating from the fetal pituitary, to produce both cortisol and DHEA-S. In contrast to DHEA-S, which is produced in the fetal zone, cortisol originates in the definitive zone (see Figure 5-1). Toward the end of pregnancy cortisol promotes differentiation of type II alveolar cells and the biosynthesis and release of surfactant into the alveoli. Surfactant decreases the force required to inflate the lungs. Insufficiency of surfactant leads to respiratory distress in the premature infant, which can cause death. Cortisol also plays an important role in the activation of labor, increasing the release of placental CRH and prostaglandins.

OTHER HORMONES AND TRANSMITTERS

Prostaglandins and Leukotrienes

Prostaglandins are a family of ubiquitous, biologically active lipids that are involved in a broad range of physiologic and pathophysiologic responses. They are not true hormones in that they are not synthesized in one gland and transported through the circulating blood to a target organ. Rather, they are synthesized at or near their site of action. Prostaglandin E2 (PGE2) and prostaglandin F (PGF), prostacyclin, and thromboxane A2 are synthesized in the endometrium, myometrium, the fetal membranes, decidua, and placenta. PGE2 and PGF cause contraction of the uterus. Their receptors in the myometrium are downregulated during pregnancy. Prostaglandins can also cause contraction of other smooth muscles, such as those of the intestinal tract. Hence, when used pharmacologically, prostaglandins may give rise to undesirable side effects such as nausea, vomiting, and diarrhea. The amniotic fluid concentrations of PGE2 and PGF rise throughout pregnancy and increase further during spontaneous labor. Levels are lower in women who require oxytocin for induction of labor than in women going into spontaneous labor. Administration of PGE2 or PGF by various routes induces labor or abortion at any stage of gestation. Various synthetic prostaglandin derivatives are currently in use to terminate pregnancy at any stage and to induce labor at term.

Prostaglandins are thought to play a major role in the initiation and control of labor. Prostaglandin synthesis begins with the formation of arachidonic acid, an obligatory precursor of the prostaglandins of the “2” series (i.e., PGE2, PGF). Arachidonic acid is stored in esterified form as glycerophospholipid in the trophoblastic membranes. The initial step is the hydrolysis of glycerophospholipids, which is catalyzed by phospholipase A2 or C. Phospholipase A2 preferentially acts on chorionic phosphatidyl ethanolamine to release arachidonic acid (Figure 5-3). Free arachidonic acid does not accumulate. Labor appears to be accompanied by a cascade of events in the chorion, amnion, and decidua that releases arachidonic acid from its stored form and converts it to active prostaglandins. 17β-Estradiol stimulates several enzymes active in the synthesis of prostaglandins from arachidonic acid.

There are two cyclooxygenase isoenzymes referred to as COX-1, or PGHS-1, and COX-2, or PGHS-2. These isoenzymes originate from separate genes. COX-1 is expressed in quiescent cells, whereas COX-2 is inducible and is expressed at sites of inflammation upon cell activation and potentiates the inflammatory process. COX-1 mRNA expression is low in fetal membranes and does not change with gestational age, whereas COX 2 mRNA expression in the amnion increases with gestational age.

Increased phospholipase A2 activity may lead to premature labor. Endocervical, intrauterine, or urinary tract infections are often associated with premature labor. Many of the organisms producing these infections have phospholipase A2 activity, which could produce free arachidonic acid, followed by prostaglandin synthesis, which could trigger labor.

Prostaglandin synthetase inhibitors can prolong gestation. Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit phospholipase A2, whereas aspirin-like drugs inhibit cyclooxygenase. Because PGE2 keeps the ductus arteriosus open, premature closure of the ductus may occur after ingestion of NSAIDs or aspirin in large amounts or for a prolonged period of time, resulting in fetal pulmonary hypertension and death.

An additional pathway for arachidonic acid metabolism is the conversion of arachidonic acid to leukotrienes (see Figure 5-3). Both prostaglandins and leukotrienes induce decidualization, which means that they initiate changes in the endometrium to facilitate implantation of the fertilized ovum.

Although PGF is more potent in producing uterine contractile activity, PGE2 is the most potent prostaglandin for ripening the cervix by inducing changes in the connective tissue. Hence, PGE2 and its synthetic derivatives are clinically useful for cervical ripening before the induction of labor or abortion.

image Changes in Maternal Metabolism

Maternal metabolism adapts to pregnancy through endocrinologic regulation, as described subsequently.

image Parturition

Parturition means childbirth, and labor is the physiologic process by which a fetus is expelled from the uterus to the outside world.

BIOCHEMICAL BASIS OF CONTRACTION

Muscle contraction is brought about by the sliding of actin and myosin filaments fueled by adenosine triphosphate (ATP) and calcium. Although skeletal muscle requires innervation, contraction of smooth muscles such as the myometrium is triggered primarily by hormonal stimuli. Hormonal receptors have been found in the myometrial cell membrane.

The binding of oxytocin and prostaglandins to their respective receptors activates phospholipase C, which hydrolyzes phosphatidylinositol bisphosphate, a lipid present in the cell membrane, to inositol trisphosphate and diacylglycerol (Figure 5-4). Inositol trisphosphate induces release of calcium from the sarcoplasmic reticulum, an intracellular calcium storage area. The resulting high intracellular free calcium concentration enables the myofibrils of the myometrium to contract. Subsequently, the calcium is pumped back into the sarcoplasmic reticulum with the help of ATP, and more calcium may enter from the extracellular fluid through both voltage-operated and receptor-operated channels that open briefly.

Unlike the heart, in which the bundle of His is present, no anatomic structures for synchronization of contractions have been found in the uterus. Instead, contraction spreads as current flows from cell to cell through areas of low resistance. Such areas are associated with gap junctions, which become especially prominent at parturition. Estradiol and prostaglandins promote the appearance of gap junctions, whereas progesterone opposes this action of estradiol.

HORMONAL CONTROL OF GESTATIONAL LENGTH AND INITIATION OF LABOR

Gestational length is under the hormonal control of the fetus in most species. Each species, however, has not only a unique gestational length, but also unique mechanisms for controlling the length of gestation. Thus, although animal models provide important insight, they do not provide specific information concerning the control of the human gestational length or the mechanisms controlling initiation of labor.

Animal Models

Most studies have been conducted in the sheep, where the fetus appears to control the onset of labor. The fetal hypothalamus stimulates the fetal pituitary to secrete ACTH, which brings about a surge of cortisol from the fetal adrenal. The cortisol surge induces the placental enzyme 17α-hydroxylase and formation of androgens, which are estrogen precursors (see Figure 5-1), simultaneously decreasing progesterone formation. The rise in the estrogen-to-progesterone ratio leads to (1) greater secretion of prostaglandins; (2) formation of myometrial gap junctions, which provide areas of low resistance to current flow and increase coordinated uterine contractions; (3) cervical ripening; and (4) the onset of labor. Administered ACTH, glucocorticoids, or dexamethasone can also initiate parturition. Removal of the fetal pituitary or adrenal, both of which are required for the cortisol surge, results in prolonged pregnancy.

In a breed of Guernsey cows with a genetic defect resulting in fetal pituitary and adrenal dysfunction, pregnancy is prolonged, and normal vaginal delivery does not occur. In the rabbit, parturition directly follows a decline in progesterone production secondary to a decline in corpus luteum function. Abortion can be prevented by administration of progesterone.

The Human

The process of normal spontaneous human parturition can be divided into four phases.

PHASE 2: STIMULATION

Phase 2 involves a progressive cascade of events leading to a common pathway of parturition, and involving uterine contractility, cervical ripening, and decidual/fetal membrane activation. This cascade probably begins with placental production of CRH. Placental CRH synthesis is stimulated by glucocorticoids, in contrast to the inhibitory effect of glucocorticoids on maternal hypothalamic CRH synthesis. Placental CRH enters into the fetal circulation and, in turn, promotes fetal cortisol and DHEA-S production. This positive feedback loop is progressively amplified, thereby driving the process forward from fetal HPA activation to parturition and the placental production of estrogens.

For most of pregnancy, uterine quiescence is maintained by the action of progesterone. At the end of pregnancy in most mammals, maternal progesterone levels fall, and estrogen levels rise. In human and nonhuman primate pregnancies, progesterone and estrogen concentrations continue to rise throughout pregnancy until delivery of the placenta. A functional progesterone withdrawal may occur in women and nonhuman primates by alterations in progesterone receptor (PR) expression. There are two progesterone receptors (PRA and PRB) in the human myometrium. In contrast to PRB, which increases progesterone action, PRA inhibits progesterone action. The ratio of PRA to PRB in the myometrium in labor is increased, which in effect results in a progesterone withdrawal.

Functional progesterone withdrawal results in functional estrogen predominance, in part as a result of the increase in placental estrogen production. The expression of estrogen receptor (ER) isoform, ERα, is normally suppressed by progesterone, but as the expression of PRA increases relative to that of PRB, so does the expression of ERα in the laboring myometrium. The rising expression of ERα facilitates increased estrogen action. Increasing estrogen levels also enhance expression of many estrogen-dependent contraction associated proteins (CAPs), including connexin 43 (gap junctions), oxytocin receptor, prostaglandin receptors, COX-2 (which results in prostaglandin production), and myosin light-chain kinase (MLCK), which stimulate myometrial contractility and labor.

The progressive cascade of biological processes leads to a common pathway of parturition, involving cervical ripening, uterine contractility, and decidual/fetal membrane activation. Cervical ripening is largely mediated by the actions of prostaglandins, uterine contractility by the actions of gap junctions and MLCK, and decidual/fetal membrane activation by the actions of enzymes such as metalloproteinases, which ultimately lead to rupture of the membranes.